Skip to main content
    I

    Intellia Therapeutics Inc (NTLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.86
    +0.16 (+1.65%)

    Market Cap: $1.36B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Intellia Therapeutics Inc (NTLA) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Intellia Therapeutics (NTLA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Intellia Therapeutics reported EPS of -$0.91, below the -$0.82 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -5.04%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.78
    Range-$0.88 - -$0.43
    19 analysts
    Revenue Consensus
    $17.38M
    Range$6.86M - $73.08M
    17 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.83
    Range-$0.94 - -$0.56
    8 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.85+2.7%
    60d ago-$0.85+2.7%
    30d ago-$0.81-2.7%
    7d ago-$0.80-2.9%
    Current-$0.83
    Revenue Consensus
    $10.84M
    Range$7.00M - $17.00M
    7 analysts

    Next Report

    NTLA has an expected report date of Feb 24, 2027.

    NTLA Earnings Call

    The latest NTLA earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, NTLA beat 19, missed 20 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $7.16M, down 48.0% from $13.78M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.91-$0.82-$0.89 - -$0.71-10.98%MissN/A162 up, 0 downNov 5, 2026$7.16M
    Jun 30, 2026-$0.80-$0.80-$0.95 - -$0.630.00%In lineN/A1510 up, 1 downAug 6, 2026$7.66M
    Mar 31, 2026-$0.81-$0.90-$1.10 - -$0.72+10.00%BeatN/A172 up, 0 downMay 11, 2026$15.05M
    Dec 31, 2025-$0.83-$0.99-$1.10 - -$0.81+16.16%BeatN/A18N/AFeb 26, 2026$23.02M
    Sep 30, 2025-$0.92-$0.98-$1.16 - -$0.64+6.12%BeatN/A183 up, 6 downNov 6, 2025$13.78M
    Jun 30, 2025-$0.99-$1.03-$1.30 - -$0.61+3.88%BeatN/A221 up, 0 downAug 7, 2025$14.24M
    Mar 31, 2025-$1.10-$1.27-$1.49 - -$0.89+13.39%BeatN/A180 up, 1 downMay 8, 2025$16.63M
    Dec 31, 2024-$1.27-$1.32-$1.61 - -$0.86+3.52%BeatN/A235 up, 3 downFeb 27, 2025$12.87M
    Sep 30, 2024-$1.34-$1.37-$1.57 - -$1.06+2.19%BeatN/A252 up, 0 downNov 7, 2024$9.11M
    Jun 30, 2024-$1.52-$1.20-$1.44 - -$0.98-26.67%MissN/A240 up, 0 downAug 8, 2024$6.96M
    Mar 31, 2024-$1.12-$1.36-$1.58 - -$1.02+17.65%BeatN/A221 up, 0 downMay 9, 2024$28.93M
    Dec 31, 2023-$1.46-$1.44-$1.65 - -$1.01-1.39%MissN/A231 up, 0 downFeb 22, 2024N/A
    Sep 30, 2023-$1.38-$1.50-$1.78 - -$1.21+8.00%BeatN/A231 up, 1 downNov 9, 2023$11.99M
    Jun 30, 2023-$1.40-$1.33-$1.59 - -$1.15-5.26%MissN/A240 up, 0 downAug 3, 2023$13.59M
    Mar 31, 2023-$1.17-$1.38-$1.70 - -$1.17+15.22%BeatN/A250 up, 0 downMay 4, 2023$12.61M
    Dec 31, 2022-$1.40-$1.39-$1.70 - -$0.83-0.72%MissN/A251 up, 0 downFeb 23, 2023$13.57M
    Sep 30, 2022-$1.49-$1.25-$1.56 - -$0.28-19.20%MissN/A261 up, 0 downNov 3, 2022$13.27M
    Jun 30, 2022-$1.33-$1.30-$2.07 - -$0.98-2.31%MissN/A210 up, 0 downAug 4, 2022$14.03M
    Mar 31, 2022-$1.96-$1.11-$1.90 - -$0.73-76.58%MissN/A210 up, 0 downMay 5, 2022$11.25M
    Dec 31, 2021-$1.09-$0.94-$1.12 - -$0.64-15.96%MissN/A201 up, 0 downFeb 24, 2022$12.85M
    Sep 30, 2021-$0.97-$0.85-$1.20 - -$0.59-14.12%MissN/A141 up, 0 downNov 4, 2021$7.20M
    Jun 30, 2021-$1.01-$0.61-$0.81 - -$0.13-65.57%MissN/A15N/AAug 5, 2021$6.55M
    Mar 31, 2021-$0.69-$0.66-$0.75 - -$0.54-4.55%MissN/A14N/AMay 6, 2021$6.45M
    Dec 31, 2020-$0.69-$0.61-$0.77 - -$0.38-13.11%MissN/A12N/AFeb 25, 2021$6.59M
    Sep 30, 2020-$0.47-$0.57-$0.88 - -$0.26+17.54%BeatN/A12N/ANov 5, 2020$22.22M
    Jun 30, 2020-$0.61-$0.67-$0.84 - -$0.43+8.96%BeatN/A9N/AAug 6, 2020$16.26M
    Mar 31, 2020-$0.63-$0.42-$0.87 - $0.31-50.00%MissN/A10N/AMay 7, 2020$12.92M
    Dec 31, 2019-$0.57-$0.56-$0.72 - -$0.47-1.79%MissN/A10N/AFeb 27, 2020$10.94M
    Sep 30, 2019-$0.49-$0.61-$0.72 - -$0.56+19.67%BeatN/A10N/AOct 31, 2019$10.62M
    Jun 30, 2019-$0.56-$0.59-$0.79 - -$0.47+5.08%BeatN/A10N/AAug 1, 2019$11.12M
    Mar 31, 2019-$0.49-$0.57-$0.78 - -$0.48+14.04%BeatN/A7N/AMay 2, 2019$10.43M
    Dec 31, 2018-$0.43-$0.56-$0.65 - -$0.34+23.21%BeatN/A8N/AFeb 27, 2019$7.88M
    Sep 30, 2018-$0.53-$0.49-$0.63 - -$0.15-8.16%MissN/A7N/AOct 31, 2018$7.41M
    Jun 30, 2018-$0.52-$0.56-$0.59 - -$0.50+7.14%BeatN/A6N/AAug 1, 2018$7.68M
    Mar 31, 2018-$0.51-$0.56-$0.67 - -$0.44+8.93%BeatN/A6N/AMay 1, 2018$7.47M
    Dec 31, 2017-$0.61-$0.42-$0.50 - -$0.28-45.24%MissN/A5N/AMar 14, 2018$6.67M
    Sep 30, 2017-$0.44-$0.49-$0.54 - -$0.43+10.20%BeatN/A5N/AOct 31, 2017$7.32M
    Jun 30, 2017-$0.45-$0.42-$0.45 - -$0.39-7.14%MissN/A4N/AAug 1, 2017$5.92M
    Mar 31, 2017-$0.36-$0.35N/A-2.86%MissN/AN/AN/AMay 2, 2017$6.21M
    Dec 31, 2016-$0.31-$0.22N/A-40.91%MissN/AN/AN/AMar 14, 2017$5.63M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.84, after -$5.25 the year before. It was -$10.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.84N/A
    Dec 31, 2024-$5.25N/A
    Dec 31, 2023-$5.41N/A
    Dec 31, 2022-$6.18N/A
    Dec 31, 2021-$3.76N/A
    Dec 31, 2020-$2.40N/A
    Dec 31, 2019-$2.11N/A
    Dec 31, 2018-$1.99N/A
    Dec 31, 2017-$1.86N/A
    Dec 31, 2016-$10.61N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,700 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20265,71215
    2025Q4Dec 31, 20258,42620
    2025Q3Sep 30, 20254,53819
    2025Q2Jun 30, 20257,01117
    2025Q1Mar 31, 20255,12919
    2024Q4Dec 31, 20246,03615
    2024Q3Sep 30, 20246,77215
    2024Q2Jun 30, 20247,84420

    2026Q2 Earnings Call

    Opening remarks

    Jason Fredette Vice President, Investor Relations and Corporate Communications Thank you, operator, and hello, everyone. Earlier this morning, we issued a press release outlining recent business updates in our second quarter financial results. This document can be found on the Investors and Media section of Intellia's website at intelliatx.com. At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements. We ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law. Joining me on the call are John Leonard, our Chief Executive Officer; and Ed Dulac, our Chief Financial Officer. With that, I'll now turn the call over to John to begin our business discussion.

    John Leonard Chief Executive Officer Thank you, Jason, and good morning, everyone. We're excited to be speaking with you to recap the tremendous progress we made in our Phase III development programs of lonvo-z in hereditary angioedema or HAE, and nex-z in transthyretin amyloidosis or ATTR. The full results of our Phase III HAELO trial in HAE position us very well for a potential approval and launch of the world's first in vivo gene editing product in the first half of next year. We also have gained important new genomic insights that further our understanding of nex-z's profile and could help position us even more favorably within a large and dynamic ATTR market. Let's begin with lonvo-z. Simply put, the second quarter was a momentous period for this program. In April, we reported positive top line results from HAELO and got our rolling BLA submission underway with the FDA. This was followed by our late-breaking oral presentation at EAACI and a concurrent publication in the New England Journal of Medicine, Intellia's sixth manuscript in this prestigious journal. HAELO was an unequivocal success as we achieved statistical significance for the primary and all key secondary endpoints. More specifically, during the 6-month primary observation period, we reported an 87% reduction in mean monthly attacks for lonvo-z versus placebo. 62% of patients were entirely attack-free and therapy-free in the lonvo-z arm. A 23-point improvement was observed for the lonvo-z arm in the total angioedema quality of life score from baseline. For context, a change of just 6 points is considered to be clinically meaningful. The New England Journal manuscript also contained compelling figures and analyses underscoring the unique value proposition that could be afforded by this onetime therapy if it's approved. For instance, patient-level data demonstrated that all patients in the lonvo-z arm experienced attack rate reductions from baseline for weeks 5 to 28.

    Frequently Asked Questions About NTLA

    When is Intellia Therapeutics's next earnings date?

    Intellia Therapeutics's next earnings report is expected for Feb 24, 2027.

    Did NTLA beat earnings estimates last quarter?

    No. Intellia Therapeutics reported EPS of -$0.91 for the quarter ended Sep 30, 2026, below the -$0.82 estimate by 10.98%.

    What EPS do analysts expect from NTLA next quarter?

    The consensus EPS estimate for Intellia Therapeutics for the quarter ending Dec 31, 2026 is -$0.78 from 19 analysts, with estimates from -$0.88 to -$0.43.

    How often does NTLA beat earnings estimates?

    Intellia Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +5.26%.